National University Singapore Launches Large COVID-19 Prophylaxis Study Targeting Ivermectin & HCQ

National University Singapore Launches Large COVID-19 Prophylaxis Study Targeting Ivermectin & HCQ

The National University of Singapore serves the island nation as a tertiary hospital, clinical training center, and research center for medical and dental faculties. With 1,160 beds serving more than 670,000 outpatients and 49,000 inpatients, NUS is ranked first in Singapore & Asia Pacific and 11th in the world, according to the 2019 QA World University Rankings.  This prestigious research organization initiated a large randomized Phase III open-label prophylaxis trial among migrant workers at high-risk of COVID-19; this study is known as the DORM Trial. Among the prophylaxis under investigation, hydroxychloroquine and Ivermectin are included. The study is led by Senior Consultant, Division of Neurology, Department of Medicine at NUS, Associate professor Seet Chee Seong Raymond.

The COVID-19 Devastation

A crushing disease when in escalation, COVID-19 causes a lower respiratory tract infection dominated by symptoms of fever, cough, and sore throat.  The incubation period was estimated at between 5 to 7 days, but could last as long as 14 days. Most COVID-19 cases are mild; respiratory involvement has been reported in about 5% of the population, requiring supplementary oxyg...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee